Last reviewed · How we verify
NCT05596968
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
trial testing Sorafenib in Acute Myeloid Leukemia With FLT3/ITD Mutation in 37 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Nanfang Hospital, Southern Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 37 |
| Start date | 1 October 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sorafenib (SORAFENIB) — full drug profile →
Conditions studied
- Acute Myeloid Leukemia With FLT3/ITD Mutation — all drugs for Acute Myeloid Leukemia With FLT3/ITD Mutation →
- Allogeneic Hematopoietic Stem Cell Transplantation — all drugs for Allogeneic Hematopoietic Stem Cell Transplantation →
Sponsor
Nanfang Hospital, Southern Medical University
Who can join
Adults 18 to 65, any sex, with Acute Myeloid Leukemia With FLT3/ITD Mutation or Allogeneic Hematopoietic Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective trial investigates the effect of sorafenib maintenance therapy in FLT3-ITD positive AML patients after allo-HSCT in terms of gut microbiome.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Role of Gut Microbiome in Cancer Treatment.
Mishra V, Mishra Y. · · 2024 · cited 4× · PMID 39282183 · DOI 10.1007/s12088-024-01340-4 -
BMAL1-depletion remodels ceramide metabolism to regulate ferroptosis and sorafenib chemosensitivity in acute myeloid leukemia.
Zheng H, Lin Z, Wang D, Zhang J, et al · · 2025 · cited 3× · PMID 40241743 · DOI 10.1016/j.isci.2025.112054 -
Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML-One Step Closer to Personalized Medicine.
Nowicka A, Tomczak H, Szałek E, Karbownik A, et al · · 2025 · cited 1× · PMID 40722831 · DOI 10.3390/biomedicines13071761
Verify or expand the search:
- PubMed search for NCT05596968
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sorafenib
Trials testing the same drug.
- NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
- NCT06474663 — A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabi · Phase 1 · withdrawn
- NCT06690697 — Combination of Toripalimab and JS004 Therapy for ccRCC · Phase 2 · recruiting
- NCT06177496 — Influence of Sarcopenia in Hepatocellular Carcinoma Patients · unknown
- NCT05033522 — Immunotherapy for Advanced Liver Cancer · Phase 2, PHASE3 · suspended
Other recruiting trials for Acute Myeloid Leukemia With FLT3/ITD Mutation
Currently open trials in the same condition.
- NCT06222580 — SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurren · Phase 1 · recruiting
Other Nanfang Hospital, Southern Medical University trials
Trials by the same sponsor.
- NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
- NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
- NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05596968 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
- Last refreshed: 27 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05596968.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing